Prof. Dr. med. Manuela Albisetti was born and raised in Ticino, Switzerland. She studied Medicine at the University of Zurich where she acquired an FMH title in Pediatrics in 1995. Until 1998 she was a senior physician at the University Children’s Hospital in Zurich. From 1999 to 2001 she participated in a research fellowship at the pediatric thrombophilia program of the Hamilton Civic Hospital Research Centre of the McMaster University in Hamilton, Canada as well as the Division of Hematology and Oncology at the Hospital for Sick Children in Toronto, Canada. Since her return to the University Children’s Hospital in Zurich in 2001, she has led the thrombophilia, anticoagulation and hemophilia outpatient clinic. In 2008 she received the Venia Legendi for Pediatrics, specifically Hemostaseology, from the Medical Faculty of the University of Zurich. In 2015 she achieved the professorship at the University of Zurich.
Prof. Albisetti is currently co-chair of the Society of Thrombosis and Haemostasis Research (GTH) and vice chairman of the Hemophilia Certification Committee of the GTH. She has been co-chair of the International Society on Thrombosis and Haemostasis (ISTH) Pediatric/Neonatal Scientific and Standardization Committee (SSC) was co-founder and president of the Swiss Haemophilia Network.
Since 2001, Prof. Albisetti was involved in several national and international panels establishing guidelines on the structure and quality process of haemophilia centres, the use of emicizumab in haemophilia patients with and without inhibitors, paediatric stroke, and supportive care and anticoagulation of children with covid-19-related disorders. Prof. Albisetti has been also involved in several national and international advisory boards and steering committees on pediatric thrombotic and bleeding disorders. She also served as consultant for investigation plans on the new oral direct anticoagulants of different pharmaceutical companies (edoxaban, Daiichi Sankyo; dabigatran, Boehringer Ingelheim). She was a member of the Data Monitoring Committee for the pediatric phase I study on rivaroxaban and direct involved as coordinating and/or principal investigator on phase I, II and III studies on dabigatran and rivaroxaban in children. Other specific research interests include the incidence and risk factors of catheter-related venous and arterial thrombosis in children.